0000000000188350

AUTHOR

Jan Poolman

showing 5 related works from this author

International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georg…

2009

An international meeting on Bordetella pertussis assay standardization and harmonization was held at the Centers for Disease Control and Prevention (CDC), Atlanta, GA, 19-20 July 2007. The goal of the meeting was to harmonize the immunoassays used for pertussis diagnostics and vaccine evaluation, as agreed upon by academic and government researchers, regulatory authorities, vaccine manufacturers, and the World Health Organization (WHO). The primary objectives were (1) to provide epidemiologic, laboratory, and statistical background for support of global harmonization; (2) to overview the current status of global epidemiology, pathogenesis and immunology of pertussis; (3) to develop a consen…

Settore MED/07 - Microbiologia E Microbiologia ClinicaBordetella pertussisStandardizationVaccine evaluationU.S.HarmonizationMedical and Health SciencesArticleBordetella pertussisPertussis vaccinesVirologyHumansMedicineCenters for Disease Control and PreventionWhooping coughLicensureGovernmentMedical educationWhooping coughAgricultural and Veterinary SciencesGeneral VeterinaryGeneral Immunology and MicrobiologybiologyClinical Laboratory Techniquesbusiness.industryPublic Health Environmental and Occupational HealthStandardization of serologic assaysBiological Sciencesbiology.organism_classificationmedicine.diseaseUnited StatesAtlantaInfectious DiseasesImmunologyBordetella pertussis Whooping cough Standardization of serologic assays ELISA Pertussis vaccinesMolecular MedicineELISAbusinessVaccine
researchProduct

Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.

2011

Conjugate vaccines using diphtheria toxoid variant (CRM(197)), diphtheria toxoid and tetanus toxoid (TT) as carrier protein may induce immune interactions (interference or impairment as measured by lower antibody levels, or enhancement [higher antibody levels]) when coadministered with other vaccines. Immune enhancement occurs when two TT conjugates are coadministered. CRM(197) conjugate vaccines induce immune bystander interference when given with diphtheria-tetanus-acellular pertussis vaccines, which reduces responses to coadministered Haemophilus influenzae type b vaccine conjugated to TT. These bystander effects are greater as the amount of CRM(197) administered increases. When large am…

Diphtheria ToxoidImmunologyMeningococcal vaccinecomplex mixturesImmune systemAdjuvants ImmunologicBacterial ProteinsDrug DiscoverymedicineBystander effectTetanus ToxoidHumansDrug InteractionsImmunization SchedulePharmacologyDiphtheria toxinDrug CarriersVaccines ConjugateTetanusbusiness.industryToxoidmedicine.diseaseVirologyVaccinationPneumococcal vaccineImmunologyBacterial VaccinesMolecular MedicinebusinessExpert review of vaccines
researchProduct

A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugat…

2009

Meningococcal disease incidence is highest in young children, yet a tetravalent conjugate vaccine is currently not available for this age group. This study evaluated a single dose of four different ACWY-TT conjugate vaccine formulations in 240 toddlers (12-14 months) and 268 children (3-5 years) compared to licensed age-appropriate control vaccines. In toddlers, rSBA-MenC GMTs for the selected formulation were statistically higher than after monovalent-MenC-conjugate vaccine. In children, rSBA-GMTs against each serogroup were statistically higher than after tetravalent polysaccharide vaccine. The safety profile was comparable to licensed controls. The new ACWY-TT conjugate vaccine promises …

MalePediatricsmedicine.medical_specialtyMeningococcal VaccinesMeningococcal diseasePolysaccharide Vaccinemedicine.disease_causeConjugate vaccinemedicineTetanus ToxoidHumansVaccines ConjugateGeneral VeterinaryGeneral Immunology and MicrobiologyTetanusbusiness.industryImmunogenicityNeisseria meningitidisPublic Health Environmental and Occupational HealthToxoidInfantmedicine.diseaseAntibodies BacterialMeningococcal InfectionsInfectious DiseasesChild PreschoolImmunologyMolecular MedicineFemalebusinessConjugateVaccine
researchProduct

Combination vaccines containing DTPa–Hib: impact of IPV and coadministration of CRM197 conjugates

2008

Vaccination with diphtheria-tetanus-acellular pertussis (DTPa)-Haemophilus influenzae type b (Hib) combinations generally elicits anti-polyribosyl-ribitol-phosphate (PRP) antibody concentrations of more than 0.15 microg/ml, a criterion that is linked to the protection of infants against Hib disease. In the UK, vaccination with DTPa3-Hib elicited atypically low anti-PRP antibody levels and was associated with breakthrough Hib cases. While the absence of a toddler booster is considered to be a key factor explaining the lowered control of Hib disease, we propose that the coadministration of serogroup C Neisseria meningitidis conjugate vaccine (MenC)-CRM197, which coincided with the introductio…

health care facilities manpower and servicesImmunologyDiphtheria-Tetanus-acellular Pertussis Vaccinesmedicine.disease_causecomplex mixturesBacterial ProteinsAntigenConjugate vaccineImmunityDrug DiscoveryHumansMedicineDiphtheria-Tetanus-acellular Pertussis VaccinesHaemophilus VaccinesPharmacologybusiness.industryNeisseria meningitidisToxoidHepatitis Bbacterial infections and mycosesmedicine.diseaseVirologyUnited Kingdomcarbohydrates (lipids)VaccinationPoliovirus Vaccine InactivatedImmunologybacteriaMolecular MedicinebusinessExpert Review of Vaccines
researchProduct

Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concent…

2011

ABSTRACT We compared the abilities of two serological readouts, antipolysaccharide IgG antibody concentrations and opsonophagocytic activity (OPA) titers, to predict the clinical effectiveness of the 7-valent pneumococcal conjugate vaccine (7vCRM) against invasive pneumococcal disease (IPD). We also assessed the accuracy of the previously established thresholds for GlaxoSmithKline's enzyme-linked immunosorbent assay with 22F adsorption (22F-ELISA) (≥0.2 μg/ml) and OPA assay (titer, ≥8) in predicting effectiveness. We showed that following a 3-dose 7vCRM primary vaccination, the serological response rates as determined using thresholds of ≥0.2 μg/ml IgG and an OPA titer of ≥8 corresponded we…

Microbiology (medical)Heptavalent Pneumococcal Conjugate VaccineClinical BiochemistryImmunologyEnzyme-Linked Immunosorbent AssayBiologyPneumococcal conjugate vaccineImmunoglobulin GSerologyPneumococcal VaccinesImmune systemPhagocytosisHeptavalent Pneumococcal Conjugate VaccinemedicineImmunology and AllergyHumansmedicine.diagnostic_testOpsonin ProteinsVaccine ResearchVirologyAntibodies BacterialTiterImmunoassayImmunoglobulin GImmunologybiology.proteinAntibodymedicine.drugClinical and vaccine immunology : CVI
researchProduct